CURE's Clinical Trial Corner: Cervical Cancer Edition

Patients with cervical cancer and their caregivers should be aware of the various clinical trials being conducted in this disease space — particularly those they can possibly join.

Here, CURE® has rounded up some of the clinical trials in cervical cancer that are currently enrolling across the country.

Radiation Therapy With or Without Chemotherapy in Patients Who Previously Underwent Surgery

Because radiation therapy is often an effective way to treat cancer, investigators in this randomized phase III trial are examining what impact, if any, the addition of chemotherapy to radiation would have on treatment — specifically in patients with cervical cancer.

This study is being held at more than 1,000 locations around the United States and is currently enrolling patients with stage I-IIA cervical cancer.

Tecentriq (atezolizumab) Immunotherapy Given With Cisplatin During Radiation Therapy

In this phase I study from Memorial Sloan Kettering Cancer Center, researchers are investigating different dosing schedules of the immunotherapy Tecentriq, when it’s been added to a regimen of the chemotherapy drug Platinol (cisplatin), and radiation in patients with locally advanced cervical cancer.

In this trial, patients will be randomly selected for one of two treatment groups, who will receive the chemotherapy drug intravenously at different times during the course of their treatment.

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy

The combination of chemotherapy and radiation has been used to treat cervical cancer for some time. But with this phase 3 trial, investigators are currently seeking patients with high-risk early-stage cervical cancer who have also had a radical hysterectomy to study the use of chemotherapy and pelvic radiation therapy with or without additional chemotherapy.

The study is currently underway in 148 locations across the United States.

Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents

Currently enrolling in 8 locations, this open label, multi-center trial is examining how effective and well-tolerated the investigational drug tisotumab vedotin is, when used in combination with other cancer drugs, including Avastin (bevacizumab), Keytruda (pembrolizumab), or Paraplatin (carboplatin).

The trial is currently enrolling patients with recurrent or stage IVB cervical cancer, and consists of a dose escalation, where the recommended doses of the combination are determined, and an expansion.

Targeted Therapy Directed by Genetic Testing

In the phase II MATCH trial, investigators are looking into the efficacy of treatment that is directed by genetic testing in patients with solid tumors or lymphomas that have progressed after at least one line of treatment.

Since genetic testing can, in some cases, identify mutations or other abnormalities that are associated with cancer, doctors hope that treatment may be better suited to the individual when therapy is selected based on the particular genetic makeup of a tumor.